Novo Nordisk A/S (LTS:0QIU) Net Change in Cash : kr1,739 Mil (TTM As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

What is Novo Nordisk A/S Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Novo Nordisk A/S's Net Change in Cash for the three months ended in Dec. 2023 was kr-15,491 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 was kr1,739 Mil.

Novo Nordisk A/S Net Change in Cash Historical Data

The historical data trend for Novo Nordisk A/S's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk A/S Net Change in Cash Chart

Novo Nordisk A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Change in Cash

Get a 7-Day Free Trial

-218.00

-3,185.00

-1,507.00

1,934.00

1,739.00

Novo Nordisk A/S Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Change in Cash	Get a 7-Day Free Trial															-15,261.00	2,283.00	6,638.00	8,309.00	-15,491.00

Novo Nordisk A/S Net Change in Cash Calculation

Novo Nordisk A/S's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	108908	+	-43892	+	-63158	+	-119
	=	1,739

Novo Nordisk A/S's Net Change in Cash for the quarter that ended in Dec. 2023

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= 9551 + -14717 + -10116 + -209

= -15,491

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr1,739 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novo Nordisk A/S Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Novo Nordisk A/S's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Novo Nordisk A/S (LTS:0QIU) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novo Nordisk A/S (LTS:0QIU) » Definitions » Net Change in Cash

Comparable Companies

OCSE:GMAB OCSE:ZEAL OCSE:ALK B OCSE:BAVA OCSE:GUBRA OCSE:PEG VRTX REGN ASX:CSL XKRX:207940 MRNA XKRX:068270 XBRU:ARGX XBRU:UCB BNTX ALNY BGNE BMRN SZSE:300122 RPRX

Traded in Other Exchanges

NONOF:USA NVO:USA NOVOB:Mexico NVO:Mexico NOVOBc:UK NOVO B:Denmark NOV:Germany N1VO34:Brazil NNO2:Austria

Address

Novo Alle 1, Bagsvaerd, DNK, DK-2880

Website

https://www.novonordisk.com

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Novo Nordisk A/S (LTS:0QIU) Headlines

No Headlines